Financial Calendar 2016
(Oslo, Norway, 13 November 2015) Bionor Pharma ASA (OSE:BIONOR) has scheduled its financial calendar 2016 as follows:
|12 February 2016||Q4 2015 Interim Financial Report|
|15 March 2016||Annual Report 2015|
|21 April 2016||Annual General Meeting|
|11 May 2016||Q1 2016 Interim Financial Report|
|23 August 2016||Q2 2016 Interim Financial Report|
|16 November 2016||Q3 2016 Interim Financial Report|
The dates may be subject to change.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, firstname.lastname@example.org
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a possible functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II clinical trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights of Vacc-4x, i.e., the upside potential from partnering or licensing remain with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York City, New York. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.
Announcement as PDF.